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1 Passed away in September of 2007.Previously, we identiﬁed a human ST3Gal-V mRNA variant peculiarly characterized by the presence
of a translational start codon localized up-stream and in-frame with the one that is usually consid-
ered as unique translation initiation site in the human gene. In this study we demonstrate, by cDNA
transfection experiments, mutational analyses, enzyme activity assays, and endoglycosidase-H
treatments, that the in vivo expression of this transcript gives rise to two human ST3Gal-V isoforms
with distinct characteristics. Produced by a leaky scanning mechanism, they carry different N-gly-
can structures and exhibit differences in their GM3 synthase activity that might be relevant for
the modulation of GM3 cellular content.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gangliosides, a large and structurally heterogeneous family of
sialic acid (NeuAc)-containing glycosphingolipids, are ubiquitous
components of all eukaryotic cells. Mainly located in the plasma
membrane, gangliosides are not only structural components of
plasma membranes, but they also participate to cell surface events,
including cell signaling transduction, subcellular targeting, and cell
adhesion [1]. In addition, remarkable changes of ganglioside distri-
bution in cells and tissues have been reported during various both
physiological and pathological cell processes, such as cell prolifer-
ation and differentiation, apoptosis, development and oncogenesis
[1–4].
The ganglioside biosynthesis is a ﬁnely regulated process [5],
and the enzyme which plays a key regulatory role is the GM3 syn-
thase, also named ST3Gal-V or Sial-T1 (CMP-NeuAc: lactosylcera-
mide a2,3-sialyltransferase, EC 2.4.99.9). It catalyses the transfer
of a NeuAc residue to the terminal galactose of lactosylceramide
with synthesis of the ganglioside GM3, the common precursor for
nearly all of the naturally occurring ganglioside species [5]. GM3
is also involved in type 2 diabetes [6], and an homozygous loss-
of-function non-sense mutation in the human ST3Gal-V gene is
cause of an autosomal recessive infantile–onset symptomatic epi-
lepsy syndrome [7].chemical Societies. Published by E
o).ST3Gal-V is described as a Golgi membrane-bound glycopro-
tein, and the overall picture of the subcellular location of the dif-
ferent steps of ganglioside biosynthesis shows the presence of
GM3 synthase activity in both the cis/medial Golgi and the trans
Golgi network [8,9]. The different location of ST3Gal-V could
contribute to subtly control the cellular ganglioside proﬁles:
whereas the ST3Gal-V localized in the proximal Golgi seems to
be preferentially involved in the synthesis of simple gangliosides
(i.e., GM3 and GD3), the enzyme with GM3 synthase activity
localized in the distal Golgi seems to be important in the synthe-
sis of more complex GM3-derived gangliosides (i.e., GD1a, GT1a,
GT1b, GQ1b) [8–11].
Several efforts have been done to investigate the human
ST3Gal-V gene expression in different tissues, and to examine the
mechanism for transcriptional activation of ST3Gal-V gene [12–
16]. Altogether these studies indicated that the expression of the
human ST3Gal-V gene is mainly regulated at transcriptional level
resulting in the production of four mRNA variants that differ in
their 50-untranslated region, but contain a coding region producing
a protein identical in both length and primary sequence [16–18].
In 2006 we reported the identiﬁcation of a novel variant of hu-
man ST3Gal-V transcript providing the ﬁrst evidence of the possi-
ble existence of two isoforms of human GM3 synthase [19].
Isolated from human placenta and then identiﬁed in HL60-undif-
ferentiated cells, this mRNA isoform is peculiarly characterized
by the presence of a translational start codon localized up-stream
and in-frame with that one usually considered as unique transla-
tion initiation site in the human gene [19].lsevier B.V. All rights reserved.
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sion of this mRNA variant gives rise to two differentially extended
human ST3Gal-V isoforms. They are produced by leaky scanning
mechanism and exhibit differences in their GM3 synthase activity.
Moreover, the two human ST3Gal-V isoforms carry N-glycan struc-
tures with different sensitivity to endonuclease-H treatments that
might be relevant to deﬁne GM3 levels in the cell.2. Materials and methods
2.1. Expression plasmid construction
The plasmids pP-Rc/CMV and pT-Rc/CMV, containing two dif-
ferently extended open reading frame (ORF) of the human placen-
tal ST3Gal-V mRNA variant (GenBank, accession no AY152815),
were prepared as indicated [19]. pP-Rc/CMV is the construct con-
taining the ‘‘short” ORF (named P insert), that is the cDNA region
extending from nucleotides 97 to 1287 of the sequence in GenBank
containing only the downstream translation start codon (i.e.,
AUG153). pT-Rc/CMV is the construct containing the ‘‘long” ORF
(named T insert), that is the cDNA region extending from nucleo-
tides 1 to 1287 of the sequence in GenBank containing both the
in-frame translation start codons (i.e., AUG54 and AUG153). Nucleo-
tides and AUG codons are numbered according to Ref. [19].
To express the carboxy-terminally c-myc epitope-tagged hu-
man ST3Gal-V, the ‘‘short” ORF and the ‘‘long” ORF of the human
ST3Gal-V cDNA were isolated from the plasmids pP-Rc/CMV and
pT-Rc/CMV, respectively, by double digestion with HindIII and
BglII, blunted with Klenow, and ligated into the blunted, calf intes-
tinal phosphatase-treated BglII site of the vector pcDNA™ 3.1/myc-
His()A (InVitrogen, Carlsbad, CA, USA). The identity of each con-
struct (named pP-myc and pT-myc, respectively) was conﬁrmed
by restriction mapping and the structure of the insert junction
was ascertained by DNA sequencing (M-Medical Sequencing Ser-
vice, Firenze, Italy).
2.2. Mutant construct preparation
Mutated constructs, called pMut54-myc and pMut153-myc,
were prepared by speciﬁc PCR ampliﬁcations using pT-myc con-
struct as template and two couples of speciﬁc mutated oligonucle-
otides as primers. To obtain pMut54-myc we used the following:
50-GCCACCCAGGACGTGGCTTCTGTTCCAATGCCAAGT G-30 and its
reverse complementary 50-CACTTGGCATTGGAACAGAAGCCACGT
CCTGGGTGGC-30; to obtain pMut153-myc the following: 50-CCGA
GCTCAAAGCAAGGTGAGAAGGCCCAGCTTG-30 and its reverse com-
plementary 50-CAAGCTGGGCCTTCTCACCTTGCTTTGAGCTCGG-30.
Mutated nucleotides are in bold and underlined. The PCR reactions
(50 ll), containing 20 mM Tris–HCl pH 8.8, 10 mM KCl, 10 mM
(NH4)2SO4, 0.1% Triton X-100, 0.1 mg/ml BSA, 0.2 mM dNTP, 1.5
units of Pfu DNA polymerase and 125 ng of each speciﬁc mutated
primer, were carried out according the following conditions: for
mutant pMut153-myc, 25 cycles, at 95 C-30 s, 62 C-1 min,
72 C-14 m; for mutant pMut54-myc, 25 cycles, at 95 C-30 s,
72 C-14 min. The presence of the correct mutation was ascer-
tained by DNA sequencing in both directions.
2.3. Cell culture, transfection and tunicamycin treatment
COS-7 cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM l-gluta-
mine, 1% Na–pyruvate, 100 U/ml penicillin and 100 lg/ml strepto-
mycin, at 37 C. Transfections were carried out on 4  105 cells
using 4 lg of indicated plasmid DNA and 21 ll of Arrest-In™
Transfection Reagent (Open Biosystems, Huntsville, AL, USA)according to the manufacturer’s instruction. After 48 h, the cells
were harvested and lysed.
In tunicamycin experiments, COS-7 cells were transfected with
indicated plasmid DNA as previously described. Six hours after
transfection, the medium was replaced with fresh culture medium
supplemented or not with 1 lg/ml tunicamycin (Sigma). Twenty-
four hours later the cells were harvested and used to measure
the enzymatic activity.
2.4. Cell lysates and glycosidase treatments
Mutant-transfected COS-7 cells were lysed in culture dishes
with RIPA buffer for 20 min at 4 C on a rotary shaker. Collected
crude lysates were allowed to stand for another hour on ice and
then centrifuged 10 m at 10 000g at 4 C to remove nuclei and
large cell debris. Proteins were estimated according to the Lowry’s
method [20].
For peptide N-glycosidase F (PNGase-F) digestions, total cell ly-
sates (500 lg of proteins) in 50 mM sodium-phosphate, pH 7.5
and 1% SDS were incubated for 10 m at 100 C. After addition of
5 U PNGase-F (Roche, Basel, Switzerland), the reaction was carried
out at 37 C for 18 h. For digestions with endoglycosidase-H (Endo-
H), total cell lysates (500 lg of proteins) in 50 mM sodium-
citrate, pH 6 and 1% SDS were incubated for 30 m at 65 C. After
addition of 16 mU Endo-H (Roche, Basel, Switzerland), the reaction
was carried out for 1 h at 37 C.
2.5. Immunoblotting analysis
Total cell lysates (300 lg of proteins) from control and trans-
fected COS-7 cells, microsomal-enriched protein fractions
(100 lg of proteins) from pMut54 and pMut153 transfected-cells
before and after tunicamycin treatment, and N-glycosidase treated
samples were resolved by 12% SDS–PAGE, blotted on PVDF mem-
brane (Bio-Rad, Richmond, CA, USA), and immunodetected with
anti-myc monoclonal antibodies (clone 9E10, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA, USA) at a dilution of 1:500. Anti-myc
immunoreactive proteins were then pointed out with HRP-conju-
gated anti-mouse IgG polyclonal antibodies at a dilution of
1:2000 dilution and ECL Western blotting detection reagents (GE
Healthcare, Little Chalfont, UK).
2.6. Enzymatic activity assay
The enzymatic activity was determined by an in vitro radioac-
tive assay as previously described [21], using the microsomal-en-
riched protein fraction as enzyme source. Brieﬂy, control and
mutant transfected COS-7 cells, before and after tunicamycin treat-
ment, were lysed in 0.32 M sucrose. After a low speed centrifuga-
tion to remove nuclei, the supernatant was centrifuged at
100 000g for 1h at 4 C. To measure enzyme activity, the reaction
mixture (50 ll), containing 0.1 M sodium cacodylate pH 6.4,
10 mM MgCl2, 0.2% Triton CF54, 1 mM CMP-[14C]-sialic acid
(0.2 lCi, Amersham), 1 mM acceptor glycolipid substrate LacCer
(Alexis Biochemicals, San Diego, CA, USA), and membrane prepara-
tion (100 lg of proteins), was incubated at 37 C for 2 h. The
amount of incorporated [14C]-NeuAc were determined after paper
descending chromatography by liquid scintillation counting.3. Results and discussion
All the human ST3Gal-V mRNA variants identiﬁed in the adult
and fetal brain [16,18] and in TPA-treated HL60 cells [17] contain
an identical ORF encoding a protein of 362 amino acids exhibiting
GM3 synthase activity. However, the identiﬁcation, in the human
Fig. 2. Western blot analysis of the selective expression of the two human ST3Gal-V
isoforms. Total cell extracts from COS-7 cells transfected with the normal pP-myc or
pT-myc constructs (lanes P and T, respectively) or with the ‘‘mutated” pMut54-myc
or pMut153-myc constructs (lanes 54 and 153, respectively) were fractionated by
SDS–PAGE and immunodetected with anti c-myc antibodies.
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taining an additional translation start codon (from now on called
A54UG), located up-stream and in-frame with the translation initi-
ation site in all the other human ST3Gal-V mRNA variants (from
now on called A153UG), strongly suggested the existence of a differ-
ent isoform of the enzyme [19]. This new isoform, consisting of 395
amino acids (‘‘long” form), would retained unaltered the large
COOH-terminal domain of 329 amino acids containing the catalytic
site, the single transmembrane domain of 18 amino acids and the
two potential N-glycosylation sites of the 362 amino acid protein
(or ‘‘short” form), but it would have an additional NH2-terminal
extension of 33 amino acids.
To begin the characterization of the protein encoded by the hu-
man placental ST3Gal-V mRNA, the plasmid pT-myc, which directs
the expression of the protein tagged with the antigenic c-myc epi-
tope at its C-terminus, was transfected into COS-7 cells. In agree-
ment with the molecular mass of the protein expressed in vitro
[19], western blotting analysis of cell lysates from pT-myc trans-
fected-cells with anti c-myc antibodies clearly shows the presence
of an immunoreactive protein migrating in SDS–PAGE with the
molecular mass of 48 kDa (Fig. 1, lane T); this corresponds to
the molecular mass predicted from the amino acid sequence from
the A54UG codon of the cloned cDNA (44.5 kDa) plus two possible
N-linked oligosaccharides [19]. However, in lane T it is also evident
a 45 kDa immunoreactive polypeptide that, interestingly, exhib-
its an electrophoretic mobility similar to that of the protein ex-
pressed in cells transfected with the plasmid pP-myc (Fig. 1, lane
P), the construct which directs the expression of the ‘‘short” human
ST3Gal-V tagged with the antigenic c-myc epitope at its C-termi-
nus. No proteins of 48 and/or 45 kDa are in extracts from
mock-transfected COS-7 cells (Fig. 1, lane C).
The 45 kDa protein detected in pT-myc expressing cells could
be either the unglycosylated form or the proteolytic product of the
48 kDa protein, since the difference of 3 kDa between the two
polypeptide chains is consistent with the presence of two possible
N-linked oligosaccharide chains as well as with the 33 amino acids
which constitute the NH2-terminal extension of the ‘‘long” human
ST3Gal-V isoform. On the other hand, another equally good possi-
bility is that the protein with the lower molecular mass derives
from the usage of the codon A153UG, instead of the codon A54UG,
as translational start site.Fig. 1. Western blot analysis of the human placental ST3Gal-V mRNA expression.
Total cell extracts from COS-7 cells transfected with the expression vector alone
(lane C) or with pP-myc (lane P) or pT-myc (lane T) constructs were fractionated by
SDS–PAGE and immunodetected with anti c-myc antibodies.To examine this issue an approach based on mutational analy-
ses was carried out and two mutated constructs, pMut54-myc
and pMut153-myc, were generated. pMut54-myc is the construct
where the A to G transition at position 54 of the cDNA results in
the elimination of the translational start codon A54UG leaving the
A153UG unaltered. pMut153-myc is the construct where the A to
G transition at position 153 of the cDNA introduces a Met to Val
substitution in the protein sequence eliminating the A153UG codon,
but leaves unaltered the A54UG codon. As clearly evidenced by
immunoblotting analysis, pMut54-myc expressing cells show theFig. 3. GM3 synthase activity of human ST3Gal-V isoforms and effects of tunica-
mycin treatment. Microsomal-enriched protein fractions from control COS-7 cells
(samples C) and from pMut54-myc or pMut153-myc expressing cells (samples 54
and 153, respectively), before () and after (+) tunicamycin treatment, were
analysed by immunoblotting with anti-myc antibodies (upper gel), and then used
to measure the enzyme activity (histogram). Data of the enzyme activity in
pMut54-myc and pMut153-myc expressing cells are expressed as relative to the
corresponding protein levels determined by immunoblotting with anti-myc anti-
bodies. Data of enzyme activity levels in control COS-7 cells are expressed as
relative to the enzyme activity in pMut54 expressing cells. n.d. = not detected.
Fig. 4. PNGase-F and Endo-H sensitivity of human ST3Gal-V isoforms. N-glycosidase sensitivity was analyzed in total cell extracts from pMut54-myc or pMut153-myc COS-7
cells expressing cells (lanes 54 and 153, respectively) treated with (+) or without () PNGase F (Panel A) or Endo-H (Panel B), by SDS–PAGE separation of digestion products,
followed by immunoblot with anti-myc antibodies.
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consistent with the expected molecular mass of the protein whose
translation start codon is the A153UG (i.e., 45 kDa) and migrating
as the smaller polypeptide in pT-Myc transfected-cells (Fig. 2, com-
pare lane 54 to lane T). Likewise, pMut153-myc expressing cells
(Fig. 2, lane 153) show the presence of only one immunoreactive
polypeptide: it migrates in SDS–PAGE as the longer protein in
pT-myc expressing cells (Fig. 2, lane T) and its molecular mass of
48 kDa is consistent with the expected molecular mass of the
protein whose translation start codon is the A54UG codon.
Therefore, these results demonstrate that the polypeptides of
48 and 45 kDa detected in pT-myc transfected-cells are pro-
duced by the alternative usage of the A54UG and A153UG codons,
respectively, and demonstrate that two isoforms of human
ST3Gal-V can be co-expressed from a unique transcript. Up to
now we do not know how occurs the AUG codon selection in pT-
myc-expressing cells, and any hypothesis would be too speculative
at this point of knowledge. It is certain that the two isoforms in pT-
myc-expressing cells are not always expressed in the same relative
ratio. In fact, by comparing Figs. 1 and 2 we can appreciate that the
lower band in lane T of Fig. 2 is clearly stronger than the upper one,
but this does not occur in lane T of Fig. 1 where the intensity of the
bands is very similar. The variability of the relative amount of the
two isoforms in transiently transfected-cells suggests a possible
‘‘casual” selection of the translational start codon. However, fur-
ther experiments are needed to exclude the existence of one or
more cell-speciﬁc mechanisms regulating the process.pMut54-
myc and pMut153-myc transfected-cells were also examined to
assess the GM3 synthase activity of each isoform. Results are in
Fig. 3: pMut54-myc transfected-cells exhibit higher levels of GM3
synthase activity than pMut153-myc transfected-cells (2.7 fold).
Of note, the amount of the respective c-myc-tagged expressed pro-
teins in the microsomal-enriched fractions used as enzymatic
sources were at similar levels [compare lanes 54 () to 153 ()
in the immunoblotting of Fig. 3].
As the inﬂuence of N-glycan structures on enzyme activity has
been demonstrated for several glycosyltransferases [22], to exam-
ine whether the GM3 synthase activity of both isoforms was
dependent on their N-glycosylation, pMut54-myc and pMut153-
myc overexpressing cells were treated with tunicamycin, an inhib-
itor of the formation of dolichol pyrophosphate-N-acetyl glucosa-
mine resulting in the block of the N-glycosylation process, and
microsomal-enriched protein fractions were used to measure the
enzyme activity. As expected, the tunicamycin treatment abolishes
the N-glycosylation of both isoforms which are detected as a single
band with a molecular mass lower than that of the corresponding
protein from untreated cells [compare lanes 54 (+) and 153 (+) to
lanes 54 () and 153 (), respectively, in the immunoblotting of
Fig. 3], and, more importantly, it causes a remarkable reduction
in their enzyme activity (Fig. 3). Interestingly, a signiﬁcant decre-
ment of the over-expressed protein levels seems to occur aftertunicamycin treatment, suggesting a possible involvement of N-
glycans in the stability of these proteins.
To characterize the structures of N-glycan chains bound to both
isoforms cell lysates from mutated transfected-cells have been
analyzed by treatments with PNGase-F and Endo-H. Digestion
products were then analysed by separation on SDS–PAGE, followed
by immunodetection with anti-c-myc antibodies.
Immunoblotting after PNGase-F treatment (Fig. 4, Panel A)
clearly show that the 45 kDa protein in pMut54-myc expressing
cells (lane 54+) and the 48 kDa protein in pMut153-myc express-
ing cells (lane 153+) are entirely susceptible to PNGase-F digestion
resulting in a reduction in size by 3 kDa. In contrast, immuno-
blotting analysis of cell lysates after Endo-H treatment (Fig. 4, Pa-
nel B) shows that, whereas the 48 kDa protein in pMut153-myc
expressing cells is entirely sensitive to Endo-H (compare lane
153 to lane 153+), the 45 kDa protein in pMut54-myc express-
ing cells is only partially susceptible to Endo-H digestion (compare
lane 54 to lane 54+), indicating that both human ST3Gal-V iso-
forms are N-glycosylated and that, the two isoforms of human
ST3Gal-V carry different N-glycan structures.
In conclusion, this report provides the ﬁrst evidence of the exis-
tence, also in human cells, of a systemwhich produces two ST3Gal-
V isoforms having distinct characteristics from an unique tran-
script, and it prompts further studies addressed to establish how
the expression of the isoforms is regulated, and if and how the
expression of one or both isoforms might be of critical importance
for the regulation of GM3 biosynthesis under pathological and
physiological conditions, as recently hypothesised for the mouse
ST3Gal-V [23].
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